Distribution of GOPC:ROS1 and other ROS1 fusions in glioma types

Philipp Sievers^{1,2#}, Damian Stichel^{1,2#}, Martin Sill^{3,4}, Daniel Schrimpf^{1,2}, Dominik Sturm^{3,5,18}, Florian Selt^{3,5,6}, Jonas Ecker^{3,5,6}, Evelina Miele⁷, Mariëtte E. G. Kranendonk⁸, Bastiaan B. J. Tops⁸, Patricia Kohlhof-Meinecke⁹, Rudi Beschoner¹⁰, Christof M. Kramm¹¹, Martin Hasselblatt¹², Guido Reifenberger^{13,14}, David Capper^{15,16}, Pieter Wesseling^{8,17}, Till Milde^{3,5,6}, Andrey Korshunov^{1,2,3}, Olaf Witt^{3,5,6}, Stefan M. Pfister^{3,4,5}, Wolfgang Wick^{18,19}, Andreas von Deimling^{1,2}, David T. W. Jones^{3,20}, Felix Sahm^{1,2,3}

¹Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

²Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

³Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany

⁴Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

⁵Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, Germany

⁶Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany

⁷Department of Pediatric Onco-Hematology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy

⁸Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

⁹Department of Pathology, Klinikum Stuttgart, Stuttgart, Germany

¹⁰Department of Neuropathology, University of Tübingen, Tübingen, Germany

¹¹Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany

¹²Institute of Neuropathology, University Hospital Münster, Münster, Germany

¹³Institute of Neuropathology, Heinrich Heine University, Düsseldorf, Germany

¹⁴German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Germany

¹⁵Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Neuropathology, Berlin, Germany

¹⁶German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany

¹⁷Department of Pathology, Amsterdam University Medical Centers, Location VUmc and Brain Tumor Center Amsterdam, Amsterdam, The Netherlands

¹⁸Clinical Cooperation Unit Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

¹⁹Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany

²⁰Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany

Co-first author

Corresponding author:

Felix Sahm, MD, PhD

Department of Neuropathology

University Hospital Heidelberg

and

Clinical Cooperation Unit Neuropathology (B300)

German Cancer Research Center (DKFZ)

Im Neuenheimer Feld 224

69120 Heidelberg, Germany

Fon: +49-6221 56-37886

Fax: +49-6221 56 4566

felix.sahm@med.uni-heidelberg.de

Funding

This study was supported by the Hertie Network of Excellence in Clinical Neuroscience. P.S. is a fellow of the Hertie Academy of Excellence in Clinical Neuroscience. D.T.W.J. is supported by the Everest Centre for Low-Grade Paediatric Brain Tumours (the Brain Tumour Charity, UK; GN-000382).

Conflict of Interest

There are no conflicts of interest for any authors.

Authorship statement

Experimental design: P.S., D. Stichel, S.M.P, A.v.D., D.T.W.J., F. Sahm

Implementation: P.S., D. Stichel, D.T.W.J., F. Sahm

Data analysis/interpretation: P.S., D. Stichel, M.S., D.T.W.J., F. Sahm

Sample collection: P.S., D. Sturm, F. Selt, J.E., E. M., M.E.G.K., B.B.J.T., P. K-M., R. B., C. M. K., M. H., G. R., D. C., P.W., T.M., A. K., O. W., S. M. P., W. W., A.v.D., D.T.W.J., F. Sahm

Approved final manuscript: All authors.

Word count

Main: 993 words

Keywords: Glioma; *ROS1*; *GOPC*; Fusion; DNA methylation profile

Abstract

The ROS proto-oncogene 1 (*ROS1*) gene is rearranged in various cancers. The translated fusion protein presents an attractive therapeutic target, since specific inhibitors have been approved for several tumor types. In glioma, *ROS1* fusions are frequent within infantile hemispheric glioma, and single case reports on occurrences in other glioma types exist. However, a comprehensive analysis spanning the full width of glioma types and subtypes is lacking. We here assessed the spectrum and distribution of *ROS1* fusions by screening >20,000 glioma cases for typical chromosomal alterations, with subsequent RNA-sequencing for confirmation of candidate cases. *ROS1* fusions were identified in 16 cases, from low grade pilocytic astrocytoma WHO grade 1 to glioblastoma, IDH wildtype WHO grade 4. Thus, despite being enriched in some tumor types, *ROS1* fusions are not pathognomonic for specific glioma types and may constitute a relevant target in a variety of cases.

Introduction

Gliomas are the most common primary tumors of the central nervous system (CNS). Among low-grade gliomas, mitogen-activated protein kinase (MAPK) pathway alterations are frequent and may provide a therapeutic target. Currently, mechanism-of-action based therapeutic approaches outside the MAPK pathway are scarce. However, especially patients with subtotally resected, recurrent or highly malignant tumors may substantially benefit from the identification of additional specific oncogenic drivers that not only provide insight into disease pathogenesis but also offer targets for personalized cancer therapies. The ROS proto-oncogene 1 (*ROS1*) gene encodes a receptor tyrosine kinase that is involved in chromosomal rearrangements in various cancers¹, which present an attractive therapeutic target, since specific inhibitors have been approved for several entities^{2,3}. Data on *ROS1* fusions in glioma are limited to single cases or small series⁴⁻⁷.

Recently, an enrichment of these fusions was found in a small number of mostly gliomas in infants^{8,9}. Routine diagnostic assessment of *ROS1* status in gliomas, however, is so far restricted to a few specialized centers or molecularly informed trials¹⁰. Thus, the landscape of *ROS1* fusions across a broad series of glial tumors of all age groups has not been comprehensively studied so far. Consequently, the distribution among the various types of low- to high-grade glioma is unknown. Similarly, no data exists to determine whether *ROS1* fusion-positive gliomas, irrespective of histology, may share further biological features, potentially supporting a 'ROS1-subtype' of gliomas. Here, we investigated the presence of *ROS1* fusions in a large cohort of 20,723 patients encompassing different diagnostic entities within the spectrum of glioma, to elucidate the frequency of such fusions and the characteristics of the respective cases.

Methods and Results

To identify gliomas with structural alterations affecting chromosome 6q (around the *ROS1* locus), we systematically evaluated copy-number data of our DNA methylation dataset encompassing 20,723 gliomas, irrespective of specific entity and WHO grade (Suppl. Fig. 1 and 2). As a high proportion of *ROS1* fusions (in particular the most frequent *GOPC:ROS1*

fusion) are accompanied by a segmental loss of chromosome 6q22 in the copy-number profile, DNA methylation data were screened for a segmental loss covering that region (Suppl. Fig. 1). Automated analysis was followed by visual inspection and led to the identification of 14 potential cases. On suspicious cases, we performed RNA and targeted exome sequencing, and confirmed the presence of *ROS1* fusions in all 14 tumors (Fig. 1A). In the most common (n=11) *GOPC:ROS1* fusions (Fig. 1B), exons 1-7 or 1-4 of *GOPC* (NM_001017408) are fused in frame to exons 35-43 of *ROS1* (NM_002944). Single cases of exons 36-43 of *ROS1* fused downstream of *ZCCHC8* exons 1-2 (NM_0017612), *ARCN1* exons 1-5 (NM_001655), or *CHCHD3* exons 1-2 (NM_017812) were also observed (Fig. 1C). In all fusion events, the kinase domain of *ROS1* was retained (Fig.1B). In addition, two further *ROS1*-fused glioma samples that were already detected as such by performing RNA sequencing in a diagnostic context, after the initial screen was performed were included into subsequent analyses. One of the samples harbored a *GOPC:ROS1* fusion (with exons 1-7 of *GOPC* fused to exons 35-43 of *ROS1*) and indeed showed segmental loss of chromosome 6q22, while the other case harbored a *CEP85L:ROS1* fusion (with exons 1-12 of *CEP85L* (NM_001042475) fused exons 35-43 of *ROS1*) with a segmental gain of chromosome 6q22. In addition, we analyzed RNA sequencing data from a set of > 1000 FFPE tissue samples processed in a diagnostic setting. Here, no further gliomas harboring a *ROS1*-fusion were detected.

A t-distributed stochastic neighbor embedding (t-SNE) analysis of DNA methylation profiles alongside a broad reference set of CNS tumors¹¹ revealed that the 'ROS1 cohort' molecularly segregated into different glioma groups (Fig. 1D). Six of the samples grouped with the DNA methylation class infantile hemispheric glioma, other tumors clustered with various reference classes of glioma from low- to high-grade (Fig. 1D). Histological re-evaluation confirmed the different histological entities and underline that *ROS1* fusions are not specific to any one glioma entity. Interestingly, most of the patients harboring a fusion were children (particularly infants). Of note, however, was the finding that two classical adult IDH-wildtype glioblastomas in adult patients also harbored a *GOPC:ROS1* fusion.

Discussion

Our data show a high frequency of *ROS1* gene fusions within the DNA methylation class infantile hemispheric glioma, which is in line with recent studies^{8,9}. This clinically distinct group of gliomas (that were initially often diagnosed as glioblastomas) carries a high prevalence of gene fusions with *ROS1*, *ALK*, *NTRK1/2/3*, or *MET* as a fusion partner. However, our finding that *ROS1* fusions also occur in cases that were both histologically and epigenetically clearly pilocytic astrocytoma or IDH-wildtype glioblastoma, respectively, underscores that this event is not pathognomonic for infantile hemispheric glioma, nor limited to pediatric patients, so in that respect concerns a quite 'promiscuous' marker in that respect.

Although relatively rare in other gliomas, identification of *ROS1* fusions is important from a treatment perspective, as there are specific inhibitors available. Screening via copy-number profiling and subsequent validation using RNA sequencing provides an efficient approach to identify patients who may benefit from this targeted therapy. However, as illustrated by one of the cases that was identified by performing RNA sequencing in a diagnostic setting, not all variants of *ROS1* fusion necessarily show a deletion around the *ROS1* locus. For example, copy-neutral translocations can lead to *ROS1* fusions as well, and such cases would be

missed by screening for segmental 6q22 loss. RNA sequencing thus remains the 'gold standard' for adequate detection of these rare events.

Our findings highlight *ROS1* fusions as a rare but potentially highly relevant therapeutic target for a subset of patients with gliomas of different histological grades and biological classes. Even though these fusions have no strong diagnostic relevance, since they are not pathognomonic for a tumor type, they are in line with the increasing demand to provide predictive markers in diagnostic neuropathology. This highlights the need for expanded testing for such alterations beyond infant gliomas. It will be interesting to see whether *ROS1*-inhibitors will be effective in upcoming clinical trials for glioma patients.

Acknowledgements We thank J. Meyer, L. Hofmann and A. Habel for skillful technical assistance and the microarray unit of the DKFZ Genomics and Proteomics Core Facility for providing Illumina DNA methylation array-related services.

Fig. 1 Summary of clinico-pathological characteristics and key molecular findings in tumors with *ROS1* gene fusion (A). Schematic illustration of the *GOPC:ROS1* fusion detected in case #3 involving exons 1-7 of *GOPC* and exons 35-43 of *ROS1* (B). Circos plot of gene fusions targeting *ROS1* (Lines link fusion gene partners according to chromosomal location; C). t-distributed stochastic neighbor embedding (t-SNE) analysis of DNA methylation profiles of *ROS1*-fused glioma alongside selected reference samples (D). Reference DNA methylation classes: posterior fossa pilocytic astrocytoma (LGG, PA PF), hemispheric pilocytic astrocytoma and ganglioglioma (LGG, PA/GG ST), midline pilocytic astrocytoma (LGG, PA MID), polymorphous low-grade neuroepithelial tumor of the young (PLNTY), ganglioglioma (LGG, GG), diffuse leptomeningeal glioneuronal tumor subgroup 1 (DLGNT 1), diffuse leptomeningeal glioneuronal tumor subgroup 2 (DLGNT 2), infantile hemispheric glioma (IHG), extraventricular neurocytoma (EVNYCT), dysembryoplastic neuroepithelial tumor (LGG, DNT), rosette-forming glioneuronal tumor (LGG, RGNT), myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle (MYXGNT), diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (DGONC), anaplastic astrocytoma with piloid features (ANA PA), pleomorphic xanthoastrocytoma (PXA), glioblastoma IDH wildtype subclass RTK I (GBM, RTK I), glioblastoma IDH wildtype subclass RTK II (GBM, RTK II), glioblastoma IDH wildtype subclass mesenchymal (GBM, MES). The two *ROS1*-fused glioma samples that were already detected as such by performing RNA sequencing in a diagnostic context are highlighted in blue. Other abbreviations: LGG/LGGNT, low-grade glioma/low-grade glioneuronal tumor; HGG, high-grade glioma; GBM, glioblastoma; PF, posterior fossa; N/A, not available.

References

1. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. *Clin Cancer Res.* 2013; 19(15):4040-4045.
2. Das A, Cheng RR, Hilbert ML, et al. Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma. *Cancer Growth Metastasis.* 2015; 8:51-60.
3. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med.* 2014; 371(21):1963-1971.
4. Richardson TE, Tang K, Vasudevaraja V, et al. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors. *J Neuropathol Exp Neurol.* 2019; 78(12):1089-1099.
5. Nakano Y, Tomiyama A, Kohno T, et al. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma. *Brain Tumor Pathol.* 2019; 36(1):14-19.
6. Davare MA, Henderson JJ, Agarwal A, et al. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. *Clin Cancer Res.* 2018; 24(24):6471-6482.
7. Cocce MC, Mardin BR, Bens S, et al. Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3). *Genes Chromosomes Cancer.* 2016; 55(9):677-687.
8. Guerreiro Stucklin AS, Ryall S, Fukuoka K, et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. *Nat Commun.* 2019; 10(1):4343.
9. Clarke M, Mackay A, Ismer B, et al. Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. *Cancer Discov.* 2020.
10. Wick W, Dettmer S, Berberich A, et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro Oncol.* 2019; 21(1):95-105.
11. Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. *Nature.* 2018; 555(7697):469-474.